Moreover, ATRA also targets the hallmark genetic abnormality in ARMS, inhibiting the PAX3-FOXO1 fusion protein’s expression and activity, thus disrupting oncogenic signaling and facilitating differentiation [49]. Here, FOXO1 is linked to alveolar rhabdomyosarcoma.